（产品说明）
蛋白名称：Human B7-H3 Protein (ECD, His Tag, Site-Specific PE Conjugation)
蛋白构建：A DNA sequence encoding the human B7-H3 (Q5ZPR3-1) (Met1-Thr461) was expressed with a polyhistidine tag at the C-terminus. The protein is site-specifically labeled with PE (Excitation= 495 - 566 nm, Emission Max.= 575 nm).
表达宿主：HEK293 Cells
蛋白纯度：0
蛋白活性：1.5e5 of 293-CAR cells expressing the anti-B7-H3 scFv can be directly stained with 100 μL (2 μL stock solution diluted to 100 μL FCM buffer) of PE-labeled recombinant human B7-H3 protein (Cat. No. 11188-H86H-SP) and the percentage of CAR-expressing cells can be detected by flow cytometry. Non-transduced 293 cells was used as a control (QC tested). 2.5e5 of PBMCs can be stained with anti-CD3 antibody and PE-labeled recombinant human B7-H3 protein (Cat. No. 11188-H86H-SP) and detected by flow cytometry (QC tested). 3.Flow cytometric analysis of anti-B7-H3 CAR expression. HEK293 cells were lentivirally transduced with anti-B7-H3 CAR. Flow cytometric analysis was performed with a negative control protein and PE-conjugated human B7-H3 protein (Site-Specific Conjugation, ECD, His Tag, Cat. No. 11188-H86H-SP), respectively. Non-transduced 293 cells were used as a control (left). 4.Binding activity of PE-conjugated B7-H3 protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and PE-conjugated human B7-H3 protein (Site-Specific Conjugation, ECD, His Tag, Cat. No. 11188-H86H-SP) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left).
蛋白内毒素：< 1.0 EU per μg of the protein as determined by the LAL method
预测N端：Leu 29
蛋白分子量：The recombinant human B7-H3 consists of AA Met1-Thr461 with a polyhistidine tag at the C-terminus. It has a predicted molecular mass of 50 kDa.
蛋白NP号：Q5ZPR3-1
蛋白氨基酸序列：Met1-Thr461
蛋白标签：C-His
蛋白保存条件：Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 3 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles.

北京义翘神州科技股份有限公司（简称：义翘神州，品牌：Sino Biological）于2021年8月16日成功登陆深圳证券交易所创业板（股票代码：301047），是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。

义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供“一站式”生物试剂产品和技术服务。客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲等地建立了子公司，在上海建立分公司，已成为生物试剂行业国内领先的科技公司之一。

凭借多年病毒蛋白研究技术优势，义翘神州仅用35天就成功表达出新冠病毒重要靶点受体结合域蛋白。为了更好的支持新冠病毒研究，义翘神州已开发生产近百种新冠病毒相关科研试剂，包括重要靶点抗原蛋白、中和抗体、抗原蛋白检测试剂盒等。义翘神州还可以提供新冠假病毒中和检测服务，可用于筛选出具有中和活性的抗体或血清，支持在细胞水平上的评估。目前，这些科研试剂已被全球数百家研究机构用于疫苗和抗体开发及基础机制研究。